CC
MRSN

Commodore Capital’s Mersana Therapeutics MRSN Stock Holding History

Commodore Capital’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-89,775
Closed -$2.85M – 36
2023
Q3 		$2.85M Buy
+89,775
New +$4.27M 0.33% 28
2021
Q3 		– Sell
-17,169
Closed -$5.83M – 33
2021
Q2 		$5.83M Hold
17,169
– – 2.03% 21
2021
Q1 		$6.95M Buy
17,169
+10,816
+170% +$5.25M 2.77% 16
2020
Q4 		$4.23M Buy
+6,353
New +$3.53M 2.3% 22

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Commodore Capital's MRSN Position: Q4 2023 in Review

Commodore Capital sold out of Mersana Therapeutics (MRSN) in Q4 2023, closing a stake of 89,775 shares — an estimated $2.85M sold.

Commodore Capital first reported a position in MRSN in Q4 2020 and held it in 4 quarters. The position peaked at $6.95M in Q1 2021. 105 funds tracked by Wall St. Rank hold MRSN as of Q4 2023.

  • Commodore Capital reported no remaining Mersana Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Commodore Capital sold 89,775 Mersana Therapeutics shares in Q4 2023, an estimated $2.85M.
  • Commodore Capital first reported a position in Mersana Therapeutics in Q4 2020 and held it in 4 quarters.
  • Commodore Capital's Mersana Therapeutics position peaked at $6.95M in Q1 2021.
  • 105 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2023.

Based on Commodore Capital's 13F filing for Q4 2023, filed 14 Feb 2024.